Rainer Blair, Danaher president and CEO (Lintao Zhang/Getty Images)
August 28, 2023 09:34 AM EDTUpdated 10:37 AM
Deals

Ab­cam agrees to $5.7B sale to Dana­her amid founder's push for a board seat

Kyle LaHucik

Senior Reporter

Dana­her will buy Ab­cam, a re­search tools sup­pli­er re­lied up­on by many bio­phar­mas, for an en­ter­prise val­ue of about $5.7 bil­lion, the com­pa­nies an­nounced Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times